The EU must consider the risks and budget impact of its e-health drive
This article was originally published in Scrip
Executive Summary
The latest EU drive to implement a cohesive and comprehensive plan for the introduction of an electronic health system across the Community is laudable and a definitive cost-saver in the long term. But the recently-published brochure from the Swedish presidency, entitled “eHealth for a healthier Europe” is as remarkable for its clear recommendations as it is for its self-confessed exclusions.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.